CLLSA response to the NICE negative draft recommendation for Ibrutinib to treat Chronic Lymphocytic Leukaemia (CLL)

We are extremely disappointed with the preliminary decision by the National Institute for Health and Care Excellence (NICE) not to recommend Imbruvica® (Ibrutinib) for treating chronic lymphocytic leukaemia (CLL) patients who have had at least one prior therapy or, for people with 17p deletion or TP53 mutation and for whom chemo-immunotherapy is unsuitable.     

CLL patients have historically had limited access to effective and innovative treatments. If this decision is not reversed following the next consultation process, the health of CLL patients could be seriously affected.

Help with Membership Login


 Joining for the first time

New visitors can register for membership using the join menu see lower right on the lower menu. An email will be sent containing a time limited (24hrs) link to your profile. Use the first link in the email to access your profile and update your details and then the second link to take you to the page where you can create a password and username.

CLL Support Association responds to NHS consultation on the proposals for the new Cancer Drugs Fund operating model

‘The aim of the new CDF is to help patients receive new treatments with genuine promise, while real world evidence is collected for up to two years on how well they work in practice. This will then help determine whether the treatment should be accepted for routine use in the NHS in the future.

The original CDF was established in 2011 to fund cancer drugs in England that are not currently approved by NICE.


NHS England consultation on Cancer Drugs Fund

NHS England and NICE ask for views on the future direction of the Cancer Drugs Fund

As part of the NHS consultation CLL support Association will be assessing the proposals in detail over the next few weeks, attending briefing meetings and are preparing a CLLSA consulation response and continuing to work with the Blood Cancers Alliance. Further information will be published in due course.

The Future of the Cancer Drugs Fund, about the consultation and proposed changes to how the Cancer Drugs Fund will be operated: